HOME >> MEDICINE >> NEWS
Kidney transplant proposal reduces wait from 24 to 14 months, improves equity for blacks & women

A proposed new system for assigning kidneys to patients waiting for transplants would reduce the median waiting time for transplantation from approximately 24 to 14 months and improve equity for African-Americans and women, according to the author of a study published in a journal of the Institute for Operations Research and the Management Sciences (INFORMS®).

The proposal, an alternative to the system currently employed by the United Network of Organ Sharing (UNOS), would also increase the overall likelihood of transplantation from 45% to 61% and increase quality-adjusted life expectancy from 32.7 months to 33.9 months.

"We developed a mathematical model that describes the dynamics of the patient group with renal disease and superimposes a system that maximizes length and quality of life," explains Prof. Lawrence M. Wein of MIT, a co-author. "The model also minimizes inequity in waiting time and inequity in the likelihood of transplantation.

"Our model leads us to propose a new policy that assigns priorities using a mixture of efficiency points and equity points that are similar to the one used by UNOS. But we add a larger set of historical information about the patient and donor characteristics and their relationship to chance of a successful transplant. We also add points to reduce disparities between different groups." Using the proposed operations research system, when a new cadaveric kidney becomes available, a statistical model computes a health benefits score for each patient. This score takes into consideration both the patient and organ characteristics used by UNOS, as well as newly added factors that include prior transplants, body size, gender, and race. The health benefits score is higher for those patients that are most likely to gain maximum benefit from the organ. The score is then adjusted so that patients who repeatedly score low on the health benefits scale can gain equal access to transplantation.

The study, "Dynamic All
'"/>

Contact: Barry List
barry.list@informs.org
410-691-7852
Institute for Operations Research and the Management Sciences
19-Jul-2000


Page: 1 2 3 4

Related medicine news :

1. Kidney cancer surgery safer at high-volume hospitals
2. Kidney transplant patients who develop diabetes show poor short-term outcomes
3. Kidney disease in diabetics relates to insulins effectiveness, say Pittsburgh researchers
4. Kidney Transplants From Living Donors Reduce Long-Term Costs Of Care
5. The Break Even Cost Of Kidney Transplants Is Shrinking
6. Kidney Transplant Recipients Require Less Long-Term Care If They Receive Well-Matched Donor Organs
7. New Strategy May Succeed At Extending The Life Of Transplanted Kidneys
8. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
9. Maternal Tissue Typing Could Improve Selection Of Kidney Transplant Donors
10. Researchers Begin Drug Trial In Hope Of Finding New Ways To Treat Acute Kidney Failure
11. Organ Rejection Drug Also Shows Promise For The Treatment Of Kidney Disease

Post Your Comments:
(Date:6/17/2013)... According to a June 11, 2013 ABC News article, ... information surfaces about the negative effects of sun on ... one’s skin care routine, as the sun's rays ... , “I agree with the article's suggestions for the best ... of Epione Beverly Hills. “Apply a minimum of SPF 30, ...
(Date:6/17/2013)... Harvard Stem Cell Institute (HSCI) researchers have identified in ... to regulate embryonic stem cell self-renewal, beginning a creative ... , The gene, SALL4, gives stem cells their ability ... mature cells. Typically, cells only express SALL4 during embryonic ... cases of acute myeloid leukemia and 10 to 30 ...
(Date:6/17/2013)... childhood obesity, researchers at the Johns Hopkins Bloomberg ... are important. A systematic review of childhood obesity ... incorporate schools and focus on both diet and ... in children. The results of the study appear ... "In measuring the effectiveness of community-based programs that ...
(Date:6/17/2013)... pyrvinium pamoate inhibits aggressive forms of prostate cancer that ... conducted in an animal model. The results will be ... in San Francisco. , "Our novel prostate cancer drug ... lead author Jeremy Jones, PhD, assistant professor of molecular ... Duarte, CA. "Thus, it has the potential to treat ...
(Date:6/17/2013)... Reliable services of Link to Pay have been offered to ... can fix payment processing. , Schools and colleges have a ... fees from students and processing them may be a herculean ... cases, colleges and universities are looking for some smart solutions ... efficiently without any complications. , At the same time, parents ...
Breaking Medicine News(10 mins):Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:A new target for cancer drug development 2Health News:Community-based programs may help prevent childhood obesity 2Health News:New medication treats drug-resistant prostate cancer in the laboratory 2Health News:PayCanada Offers Link to Pay Services to its Customers 2
(Date:6/17/2013)... TORONTO , June 17, 2013  Generex ... it entered into a securities purchase agreement with certain ... agreed to purchase in a private placement an aggregate ... Series E 9% Convertible Preferred Stock ("convertible preferred stock") ... 100% of the shares of its common stock issuable ...
(Date:6/17/2013)... -- Franciscan St. Francis Health Cancer Center today ... Indiana to use a new drug to treat ... Xofigo ®, a radiopharmaceutical used in patients with late-stage, ... was approved for use by the U.S. Food and Drug ... it may become castration-resistant, which has become resistant to medical ...
(Date:6/17/2013)... OSAKA, Japan , June 17, 2013 ... Takeda Pharmaceuticals U.S.A. , Inc. today ... KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and ... the United States (U.S.). These ... Administration (FDA) for the treatment of type 2 diabetes ...
Breaking Medicine Technology:Generex Announces $1,225,000 Capital Investment 2Generex Announces $1,225,000 Capital Investment 3Generex Announces $1,225,000 Capital Investment 4Generex Announces $1,225,000 Capital Investment 5New drug proving effective in attacking advanced prostate cancer 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 3Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 4Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 5Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 6Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 7Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 8Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 9
Cached News: